BackKiniksa Pharmaceuticals International Plc. Overview

Kiniksa Pharmaceuticals International Plc. Total Assets

Kiniksa Pharmaceuticals International Plc.'s total assets is $900M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$896.11M
35.54% YoYΔ $234.96M vs prior year quarter

Peer average

Loading

Kiniksa Pharmaceuticals International Plc. Total Assets History

Loading

Kiniksa Pharmaceuticals International Plc. vs. peers: Total Assets Comparison

Loading

Kiniksa Pharmaceuticals International Plc. Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kiniksa Pharmaceuticals International Plc. (KNSA) FAQ

As of the most recent data (June 2026), KNSA shows a total assets of $900M. That compares with $660M in the prior-year period — up 35.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KNSA's total assets is now $900M (was $660M) — a 35.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Kiniksa Pharmaceuticals International Plc. is outperforming or lagging.

Tracking KNSA's total assets over time shows whether Kiniksa Pharmaceuticals International Plc. is scaling, shrinking, or reshaping that part of the business. The current reading is $900M That compares with $660M in the prior-year period — up 35.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Kiniksa Pharmaceuticals International Plc.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $900M) with ownership activity and broader fundamentals.

Kiniksa Pharmaceuticals International Plc.'s total assets is $900M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.